Telmisartan-d3 |
Catalog No.GC48137
One-Click Copy Product Info
|
An internal standard for the quantification of telmisartan
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1189889-44-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Telmisartan-d3 is intended for use as an internal standard for the quantification of telmisartan by GC- or LC-MS. Telmisartan is a nonpeptide angiotensin (AT) II receptor antagonist which selectively and insurmountably inhibits the AT II receptor subtype AT1 (Ki = 3.7 nM).1 It also acts as a partial agonist of peroxisome proliferator-activated receptor gamma (PPARγ), activating the receptor to 25-30% of that produced by the full agonist rosiglitazone .2 Through these actions, telmisartan potently reduces blood pressure in various animal models of hypertension, diminishing cardiac hypertrophy, cardiovascular and renal risk, and glomerulosclerosis.3,4,5
1.Wienen, W., Hauel, N., Van Meel, J.C.A., et al.Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277Br. J. Pharmacol.110245-252(1993) 2.Benson, S.C., Pershadsingh, H.A., Ho, C.I., et al.Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activityHypertension43(5)993-1002(2004) 3.McClellan, K.J., and Markham, A.TelmisartanDrugs56(6)1039-1044(1998) 4.Jugdutt, B.I.Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderlyClin. Interv. Aging5403-416(2010) 5.Schmieder, R.E., Bakris, G., and Weir, M.R.Telmisartan in incipient and overt diabetic renal diseaseJ.Nephrol.24(3)263-273(2011)
| Cas No. | 1189889-44-8 | SDF | |
| Canonical SMILES | CC1=CC(C2=NC3=C(C=CC=C3)N2C([2H])([2H])[2H])=CC4=C1N=C(CCC)N4CC5=CC=C(C6=CC=CC=C6C(O)=O)C=C5 | ||
| Formula | C33H27D3N4O2 | M.Wt | 517.6 |
| Solubility | DMF : ≥ 1.6 mg/mL (3.09 mM); DMSO : ≥ 1 mg/mL (1.93 mM); DMF:PBS (pH 7.2) (1:1) : ≥ 0.5 mg/mL (0.97 mM) | Storage | Store at 2°C to 8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.932 mL | 9.66 mL | 19.3199 mL |
| 5 mM | 386.4 μL | 1.932 mL | 3.864 mL |
| 10 mM | 193.2 μL | 966 μL | 1.932 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)